1. Home
  2. ASG vs PRTC Comparison

ASG vs PRTC Comparison

Compare ASG & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASG

Liberty All-Star Growth Fund Inc.

HOLD

Current Price

$5.38

Market Cap

334.6M

Sector

Finance

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

N/A

Current Price

$17.13

Market Cap

386.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASG
PRTC
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
334.6M
386.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ASG
PRTC
Price
$5.38
$17.13
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
324.3K
2.0K
Earning Date
01-01-0001
08-28-2025
Dividend Yield
8.09%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.20
Revenue
N/A
$6,391,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.08
Revenue Growth
N/A
1265.60
52 Week Low
$4.47
$13.30
52 Week High
$5.71
$20.00

Technical Indicators

Market Signals
Indicator
ASG
PRTC
Relative Strength Index (RSI) 54.85 53.06
Support Level $5.26 $16.64
Resistance Level $5.42 $16.99
Average True Range (ATR) 0.06 0.40
MACD 0.01 0.04
Stochastic Oscillator 86.89 54.80

Price Performance

Historical Comparison
ASG
PRTC

About ASG Liberty All-Star Growth Fund Inc.

Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: